https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40374 Wed 13 Mar 2024 08:55:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49975 Thu 22 Jun 2023 11:31:53 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:315 Sat 24 Mar 2018 07:42:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55957 0.5 ng/mL. Cox regression and Fine-Gray models were used to test whether poor PSA response was associated with metastasis-free survival, biochemical recurrence, prostate-cancer specific mortality, and overall survival. Results: Nine hundred thirty men met inclusion criteria for this analysis. Median follow-up was 130 months (interquartile range [IQR], 89-154 months). After a median of 3 months (IQR, 3-4.2 months) of neoadjuvant ADT, the median PSA was 0.60 ng/mL (IQR, 0.29-1.59). Overall, 535 men (57%) had a PSA >0.5 ng/mL. Poor PSA response was associated with significantly worse metastasis-free survival (hazard ratio [HR], 3.93; P =.02), worse biochemical recurrence (subdistribution HR, 2.39; P =.003), worse prostate-cancer specific mortality (subdistribution HR, 1.50; P =.005), and worse overall survival (HR, 4.51; P =.05). Conclusions: Patients with PSA >0.5 mg/mL after at least 3 months of neoadjuvant ADT had worse long-term clinical outcomes and should be considered for treatment intensification.]]> Fri 12 Jul 2024 10:25:39 AEST ]]>